

# 2025 GNIPST BULLETIN (Pharmacy)

Volume-2, Issue- 4



**GURU NANAK INSTITUTE OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY**

157/F, Nilgunj Road, Kolkata- 700114, West Bengal, India



# Table of Contents

1	Message from Director and Principal	1
2	Recent Researches	2
3	New Drug Approvals	3
4	Clinical Trial News	4
5	Disease Outbreak News	5
6	Campus News	6
7	Special Page	7
8	Game Time	8





## MESSAGE FROM HONORABLE DIRECTOR

As the Director of Guru Nanak Institute of Pharmaceutical Science and Technology, I extend my warmest greetings to all members of our academic family and beyond on the joyous occasion of Shuvo Noboborsho—the Bengali New Year. This time of renewal and celebration offers us an opportunity to reflect on the year gone by and embrace the coming year with hope, positivity, and a renewed sense of purpose.

At our esteemed institution, we are committed to fostering a culture of excellence, inclusivity, and innovation. As we step into a new year, we continue our dedication to nurturing inquisitive minds, promoting scientific curiosity, and empowering our students to become future leaders in the field of Pharmaceutical Sciences.

May this new year bring health, happiness, and prosperity to all. Let us walk together into 1432 with renewed enthusiasm, unwavering determination, and a shared vision for growth and success.

Shuvo Noboborsho!

Wishing you and your loved ones a year filled with peace, progress, and fulfillment.

*Prof. (Dr.) Abhijit Sengupta*

## MESSAGE FROM HONORABLE PRINCIPAL

On the joyous occasion of Shuvo Noboborsho, I extend my warm greetings and best wishes to all our students, faculty, staff, alumni, and valued partners. May the Bengali New Year bring peace, prosperity, good health, and renewed enthusiasm to your lives.

At Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST), we embrace the spirit of new beginnings with a deep commitment to academic excellence and inclusive development.

Since our establishment in 2005, GNIPST has grown to become a distinguished institution in pharmacy education, recognized by the Pharmacy Council of India (PCI), and honored as the first pharmacy college in the region to receive both NAAC and NBA accreditations. Our ranking in the National Institutional Ranking Framework (NIRF)—74th in 2024—further reflects our dedication to quality education and professional advancement.


As we welcome the Bengali year 1432, we renew our mission to nurture intellectual curiosity, promote innovation, and empower students to excel in the dynamic field of pharmaceutical sciences. At GNIPST, we are proud to offer an environment that supports personal growth, leadership, and a commitment to societal well-being.

Let this new year inspire us all to pursue our goals with integrity, passion, and purpose. We invite aspiring pharmacy professionals to become a part of our vibrant academic journey and contribute to shaping a healthier, brighter future.

Shuvo Noboborsho!

Wishing you and your loved ones a year full of joy, success, and meaningful achievements.

*Prof. (Dr.) Lopamudra Datta*





## RECENT RESEARCHES



**New WHO guidance calls for urgent transformation of mental health policies**

**MORE INFO**

[www.who.int/](http://www.who.int/)

The World Health Organization (WHO) today launched new guidance to help all countries reform and strengthen mental health policies and systems. Mental health services worldwide remain underfunded, with major gaps in access and quality. In some countries, up to 90% of people with severe mental health conditions receive no care at all, while many existing services rely on outdated institutional models that fail to meet international human rights standards. The guidance provides a clear framework to transform mental health services in line with the latest evidence and international human rights standards, ensuring quality care is accessible to all.

**Types of data requested to inform May 2025 COVID-19 vaccine antigen composition deliberations**

**MORE INFO**

[www.who.int/](http://www.who.int/)

The WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) continues to closely monitor the genetic and antigenic evolution of SARS-CoV-2 variants, immune responses to SARS-CoV-2 infection and COVID-19 vaccination, and the performance of COVID-19 vaccines against circulating variants. Based on these evaluations, WHO advises vaccine manufacturers and regulatory authorities on the implications for future updates to COVID-19 vaccine antigen composition. The next decision-making meeting of the TAG-CO-VAC is scheduled for May 2025, after which a statement on COVID-19 vaccine antigen composition and an accompanying data annex will be published on the WHO website. These meetings are timed to balance the availability of the latest epidemiological, immunological, and virological data, with the kinetics of vaccine-induced protection and the lead time manufacturers need to update the antigen composition of authorized COVID-19 vaccines.

**Decades of progress in reducing child deaths and stillbirths under threat, warns the United Nations.**

**MORE INFO**

[www.who.int/](http://www.who.int/)

The number of children dying globally before their fifth birthday declined to 4.8 million in 2023, while stillbirths declined modestly, still remaining around 1.9 million, according to two new reports released today by the United Nations Inter-agency Group for Child Mortality Estimation (UN IGME). Since 2000, child deaths have dropped by more than half and stillbirths by over a third, fuelled by sustained investments in child survival worldwide. In 2022, the world reached a historic milestone when child deaths dropped slightly below 5 million for the first time. However, progress has slowed and too many children are still being lost to preventable causes.



FDA

# NEW DRUG APPROVALS

March, 2025

**Encelto (revakinagene taroretcel-lwey) Intravitreal Implant – formerly NT-501**

- **Company:** Neurotech Pharmaceuticals, Inc.
- **Date of Approval:** March 5, 2025
- **Treatment for:** Macular Telangiectasia Type 2



**Gozellix (gallium Ga 68 gozetotide) Injection Kit**

- **Company:** Telix Pharmaceuticals Limited
- **Date of Approval:** March 20, 2025
- **Treatment for:** Positron Emission Tomography Imaging.



**Vykat XR (diazoxide choline) Extended-Release Tablets – formerly DCCR**

- **Company:** Soleno Therapeutics, Inc.
- **Date of Approval:** March 26, 2025
- **Treatment for:** Prader-Willi Syndrome



**Conexence (denosumab-bnht) Injection**

- **Company:** Fresenius Kabi USA, LLC
- **Date of Approval:** March 25, 2025
- **Treatment for:** Osteoporosis



**Omyclo (omalizumab-igec) Injection**

- **Company:** Celltrion USA
- **Date of Approval:** March 7, 2025
- **Treatment for:** Asthma, Maintenance, Chronic Rhinosinusitis With Nasal Polyps, Food Allergies, Urticaria



**Blujepa (gepotidacin) Tablets**

- **Company:** GlaxoSmithKline
- **Date of Approval:** March 25, 2025
- **Treatment for:** Urinary Tract Infection



**Qfitlia (fitusiran) Injection**

- **Company:** Sanofi
- **Date of Approval:** March 28, 2025
- **Treatment for:** Hemophilia A, Hemophilia A .



<https://www.drugs.com/newdrugs.html>

GNIPST BULLETIN 2025





# CLINICAL TRIAL NEWS



01.

## Depemokimab Delivers Clinically Meaningful and Statistically Significant Improvements for Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).

GSK plc (LSE/NYSE: GSK) today announced full results from the positive ANCHOR-1 and ANCHOR-2 phase III clinical trials assessing the efficacy and safety of depemokimab versus placebo (both with standard of care [SOC]) in adults with CRSwNP. Depemokimab is an investigational, ultra-long-acting monoclonal antibody targeting interleukin-5 (IL-5), a key cytokine (protein) in type 2 inflammation that presents in up to 85% of people with CRSwNP.

02.

## Latigo Biotherapeutics Granted FDA Fast Track Designation for LTG-001 for the Non-Opioid Treatment of Acute Pain.

Latigo Biotherapeutics ("Latigo") today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to LTG-001, the company's oral, investigational selective Na<sub>v</sub>1.8 inhibitor for the treatment of acute pain. LTG-001 works by blocking peripheral sensory neurons responsible for pain signals, thus preventing the transmission of these pain signals to the central nervous system. The FTD follows positive Phase 1 results which demonstrated a favorable safety, tolerability, and pharmacokinetic profile for LTG-001.

03.

## Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301.

Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today released Phase 3 safety data for its lead asset CTx-1301 (dexmethylphenidate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

04.

## Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (<sup>186</sup>Re) Obisbameda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company" or "Plus Therapeutics"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Rhenium (<sup>186</sup>Re) Obisbameda for the treatment of leptomeningeal metastases (LM) in patients with lung cancer.

05.

## Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy.

06.

## AZD0780, a Novel Oral PCSK9 Inhibitor, Demonstrated Significant LDL Cholesterol (LDL-C) Reduction in PURSUIT Phase IIb Trial

Positive results from the PURSUIT Phase IIb trial for AstraZeneca's AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of standard-of-care statin therapy, as compared with placebo.<sup>1,2</sup> AZD0780 is an investigational once-daily oral PCSK9 inhibitor for patients currently not reaching their LDL-C lowering goal despite standard-of-care lipid-lowering therapies such as statins.

MORE INFORMATION



[https://www.drugs.com/clinical\\_trials\\_archive/january-2025.html](https://www.drugs.com/clinical_trials_archive/january-2025.html)





# DISEASE OUTBREAK NEWS (DONS)

March, 2025

## Middle East respiratory syndrome coronavirus - Kingdom of Saudi Arabia

13 March, 2025

### Situation at a glance

This is the bi-annual update on the Middle East respiratory syndrome coronavirus (MERS-CoV) infections reported to the World Health Organization (WHO) from the Kingdom of Saudi Arabia (KSA). From 6 September 2024 to 28 February 2025, four laboratory-confirmed cases of MERS-CoV infection, including two deaths, were reported to WHO by the Ministry of Health of the KSA. One of the four cases was a secondary case exposed to the virus in a healthcare facility (nosocomial transmission). Close contacts of the four cases were followed up by the Ministry of Health. No additional secondary cases have been detected. The notification of these four cases does not alter the overall risk assessment, which remains moderate at both the global and regional levels. The reporting of these cases shows that the virus continues to pose a threat in countries where it is circulating in dromedary camels, particularly those in the Middle East.



**MORE INFO**

<https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON547>

## Measles - United States of America

27 March, 2025


### Situation at a glance

On 11 March 2025, the World Health Organization (WHO) received a report from the International Health Regulation (2005) (IHR) National Focal Point (NFP) of the United States of America (United States) on the ongoing measles outbreak in the country, notified under IHR because it is an unusual event with potential significant public health impact, with the number of cases and deaths in 2025 exceeding the numbers in previous years. Additionally, cases linked to the outbreak in the State of Texas, United States, have been reported in Mexico. Measles is a highly contagious, airborne viral disease that can lead to severe complications and death. From 1 January to 20 March 2025, 17 States have reported a total of 378 cases of measles, including two deaths - the first deaths related to measles in the United States in a decade. The majority of cases are in children who are unvaccinated or have unknown vaccination status, and the overall hospitalization rate is 17%. In 2025, within the larger public health event, there are three distinct measles outbreaks reported, accounting for 90% (341/378) of reported cases.




**MORE INFO**

<https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON548>



# CAMPUS NEWS



**1. Placement:** Our student, Arnab Chakraborty, B.Pharm, 2025 at GNIPST, placed at Win-Medicare Private Limited. We appreciated his hard work and dedication and wished him great success in this new journey.




**2. Placement:** GNIPST Student, Abantika Mondal, M. Pharm, 2025 at GNIPST, was successfully placed at Macleods Pharmaceuticals. We appreciated her hard work and dedication towards his passion, and we wish her continued success in your career.



**3. Placement:** Our Student, Nitika Kumari, **B.Sc. Biotechnology** (2025), has been placed at Cipla. We appreciated her hard work and dedication towards his passion, and we wish her continued success in your career.



**4. National Seminar:** Guru Nanak Institute of Pharmaceutical Science and Technology invited by Dr. Upendra Sharma, Principal Scientist at CSIR-Institute of Himalayan Bioresource Technology, Palampur, for enlightening us on the topic of "Phytochemical Investigation of Himalayan Medicinal Plants: Traditional Vs Advanced Approaches" on 28th March, 25 (Hybrid mode: 03:00 PM) to the GNIPST Auditorium. Dr. Sharma explored the vast medicinal potential of Himalayan plants, comparing traditional knowledge with modern scientific advancements in phytochemical research.



**5. Quiz Competition:** The Debate and Extempore Club of GNIPST announced an Intra-College QUIZ Competition on 10th April at the GNIPST Auditorium.




MORE INFORMATION  [www.gnipst.ac.in](http://www.gnipst.ac.in)

GNIPST BULLETIN 2025



# CAMPUS NEWS



**6. Industry Visit:** Guru Nanak Institute of Pharmaceutical Science and Technology organized an Industrial Visit for B.Sc. Microbiology, Biotechnology, and Genetics (3rd Year) students to Diamond Beverages Pvt. Ltd. on 4th & 5th April 2025. This visit provided students with valuable industry exposure, giving them insights into the manufacturing processes, quality control, and operational techniques of a leading beverage company.



**7. Get Set Talk | GST | JIS ke sath''** is the official JIS Podcast that brings inspiring stories, insightful discussions, and expert perspectives from please stay tuned in to explore innovation, entrepreneurship, and campus life through engaging conversations straight from the heart of JIS Group.



**8. Get Set Talk | GST | JIS ke sath''** Get Set Talk – Episode 5 featuring students of GNPST! 🎧💙  
A must-watch for students embracing the beauty of College Life! Tune in to the conversation of Classes, Career and Crushes! 💙



MORE INFORMATION >>

[www.gnipst.ac.in](http://www.gnipst.ac.in)



## POHELA BOISHAKH: THE VIBRANT CELEBRATION OF BENGALI NEW YEAR

Pohela Boishakh, also known as Bangla Shubho Noboborsho, is celebrated on the 14th or 15th of April, marking the first day of the Bengali calendar. It is a joyous occasion observed across Bangladesh and the Indian state of West Bengal, welcoming the new year with hope and cultural pride.




### Significance of Pohela Boishakh

- **New Beginnings:** Symbolizes a fresh start, leaving behind the old and embracing prosperity.
- **Cultural Festivities:** Celebrated with traditional music, dance, fairs, and colorful processions like Mongol Shobhajatra.
- **Traditional Attire:** People dress in festive clothes—men in panjabis and women in red and white sarees.
- **Rituals and Customs:** Homes and businesses are cleaned and decorated; traders perform Haal Khata by opening new accounting books.
- **Unity and Inclusiveness:** Brings together people across religions and communities.
- **Global Recognition:** Listed as a UNESCO Intangible Cultural Heritage for its cultural richness and significance.



# GNIPST GAME TIME



## WORD SEARCH: Hints: Anti-cancer drugs

C	I	S	P	L	A	T	I	N	V	R	Q
P	R	T	A	Y	P	A	H	S	I	I	F
O	Q	H	C	M	Q	M	K	F	N	T	G
K	S	B	L	N	A	O	T	H	B	U	H
G	W	N	I	O	Z	X	U	M	L	X	J
J	P	Y	T	J	S	I	O	K	A	I	W
T	Z	Q	A	G	D	F	L	J	S	M	E
Y	X	H	X	D	F	E	S	V	T	A	Y
U	C	K	E	A	C	N	W	E	I	B	U
E	D	O	L	C	H	T	S	P	N	Q	O
W	S	D	U	B	J	B	N	M	E	A	L

*Stay tuned for to the next edition for a shout out to fastest correct answers!*

**Submit your answer**



SCAN  
ME

or

CLICK  
HERE

**Cheers to the Victor!**

Volume -2, Issue -1



**Debanjan Bhattacharya**

B.Pharm, 3rd Semester

Guru Nanak Institute of Pharmaceutical Science and Technology

**Correct answers received from them also:**

1. Shaswati Ghosh
2. Neha mondal



Editor-in-Chief

*Prof. (Dr.) Abhijit Sengupta*

Managing Editors

Prof. (Dr.) Lopamura Datta

Associate Editors

Mr. Tushar Adhikari

Ms. Manjarima Ganguli

Editorial Board Members

Mrs. Indrani Banerjee Chakraborty

Mr. Arpan Dutta

Ms. Ananya Chandra

Ms. Parnasree Chakraborty

Ms. Lopamudra Saha

Mr. Sarthak Saha



## COURSES OFFERED

### PHARMACY UG COURSES

- Bachelor of Pharmacy (B.Pharm)

### PHARMACY DIPLOMA COURSES

- Diploma in Pharmacy (D.Pharm)

### PHARMACY PG COURSES

- M.Pharm in Pharmaceutics
- M.Pharm in Pharmacology
- M.Pharm in Pharmaceutical Chemistry
- M.Pharm in Quality assurance
- M.Pharm in Regulatory Affairs
- M.Pharm in Pharmacognosy
- M.Pharm in Pharmaceutical Biotechnology

Major  
Recruiters



**Latest  
news**



[www.gnipst.ac.in](http://www.gnipst.ac.in)



[www.facebook.com](http://www.facebook.com)



[www.instagram.com](http://www.instagram.com)



[www.linkedin.com](http://www.linkedin.com)



[www.youtube.com](http://www.youtube.com)



[api.whatsapp.com](http://api.whatsapp.com)

